Bio Path Holdings Inc (BPTH)

[SJSTOCKSHARK]

More news. It looks like the drop to below a buck just before the ASM has finally caused the company to act.

HOUSTON, Nov. 04, 2016 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc.(BPTH), , a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming poster presentation at the 2016 American Society of Hematology (ASH) Annual Meeting, taking place from December 3-6, 2016 in San Diego, CA.


Dr. Ana Tari Ashizawa, Director of Research at Bio-Path(BPTH), will present preclinical and clinical data of BP1001 (Liposomal Grb2 antisense) for the treatment of chronic myeloid leukemia (CML).

Details for the poster presentation are as follows:

Date: Monday, December 5, 2016
Presentation Time: 6:00 pm – 8:00 pm Pacific Time
Location:San Diego Convention Center, Hall GH
Session: Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy
Abstract: 4293
Title: “BP1001, a Novel Therapeutic for Chronic Myelogenous Leukemia” (Link to abstract)

About Bio-Path Holdings, Inc.(BPTH)